Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience.

Afshar M, Evison F, James ND, Patel P.

Urol Oncol. 2015 Aug;33(8):338.e1-7. doi: 10.1016/j.urolonc.2015.05.003.

PMID:
26059077
2.

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.

Omlin A, Pezaro C, Mukherji D, Mulick Cassidy A, Sandhu S, Bianchini D, Olmos D, Ferraldeschi R, Maier G, Thompson E, Parker C, Attard G, de Bono J.

Eur Urol. 2013 Aug;64(2):300-6. doi: 10.1016/j.eururo.2012.12.029.

PMID:
23313031
3.

Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.

Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW.

Cancer. 2013 Aug 15;119(16):2990-8. doi: 10.1002/cncr.28102.

4.

Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.

Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, Shore N, Oudard S, Karsh L, Carducci M, Damião R, Wang H, Ying W, Goessl C.

Eur Urol. 2015 Jul;68(1):42-50. doi: 10.1016/j.eururo.2014.10.001.

PMID:
25449207
5.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology..

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Review.

PMID:
24321502
6.

Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.

Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, Freedland SJ.

Cancer. 2014 Jan 15;120(2):197-204. doi: 10.1002/cncr.28423. Erratum in: Cancer. 2015 Dec 1;121(23):4272.

7.

Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.

Grenader T, Plotkin Y, Gips M, Cherny N, Gabizon A.

Oncol Rep. 2014 Jan;31(1):428-34. doi: 10.3892/or.2013.2852.

PMID:
24247716
8.

Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials.

West TA, Kiely BE, Stockler MR.

Eur J Cancer. 2014 Jul;50(11):1916-24. doi: 10.1016/j.ejca.2014.04.004. Review.

PMID:
24825113
9.

The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.

Bourdoumis A, Chrisofos M, Stasinou T, Christopoulos P, Mourmouris P, Kostakopoulos A, Deliveliotis C.

Anticancer Res. 2015 May;35(5):3075-9.

PMID:
25964598
10.

Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.

Koo KC, Park SU, Kim KH, Rha KH, Hong SJ, Yang SC, Chung BH.

Yonsei Med J. 2015 Sep;56(5):1206-12. doi: 10.3349/ymj.2015.56.5.1206.

11.

Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.

Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ.

Prostate. 2014 Jun;74(8):820-8. doi: 10.1002/pros.22788.

PMID:
24668612
12.

The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer.

Ranasinghe WK, Sengupta S, Williams S, Chang M, Shulkes A, Bolton DM, Baldwin G, Patel O.

Cancer Med. 2014 Apr;3(2):245-51. doi: 10.1002/cam4.189.

13.

Characterising the castration-resistant prostate cancer population: a systematic review.

Kirby M, Hirst C, Crawford ED.

Int J Clin Pract. 2011 Nov;65(11):1180-92. doi: 10.1111/j.1742-1241.2011.02799.x. Review.

PMID:
21995694
14.

Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.

Hernandez RK, Cetin K, Pirolli M, Quigley J, Quach D, Smith P, Stryker S, Liede A.

Can J Urol. 2015 Aug;22(4):7858-64.

PMID:
26267023
15.

External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer.

Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, Kobayashi M, Morita T.

BMC Urol. 2014 Apr 18;14:31. doi: 10.1186/1471-2490-14-31.

16.

Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer.

Qu Y, Dai B, Ye D, Kong Y, Chang K, Jia Z, Yang X, Zhang H, Zhu Y, Shi G.

Sci Rep. 2015 Jan 7;5:7654. doi: 10.1038/srep07654.

17.

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.

Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, Forer D, Hirmand M, de Bono JS.

Lancet Oncol. 2014 Sep;15(10):1147-56. doi: 10.1016/S1470-2045(14)70303-1. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.

PMID:
25104109
18.

Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.

Kim M, Lee J, Jeong CW, Ku JH, Kim HH, Kwak C.

Urol Oncol. 2015 May;33(5):203.e1-9. doi: 10.1016/j.urolonc.2015.01.017.

PMID:
25726498
19.

Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.

Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, Clayton R, Heng DY, Joshua AM, Chi KN.

Eur Urol. 2015 Mar;67(3):441-7. doi: 10.1016/j.eururo.2014.01.030.

PMID:
24508071
20.

Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.

Loriot Y, Eymard JC, Patrikidou A, Ileana E, Massard C, Albiges L, Di Palma M, Escudier B, Fizazi K.

Eur J Cancer. 2015 Sep;51(14):1946-52. doi: 10.1016/j.ejca.2015.06.128.

PMID:
26208462
Items per page

Supplemental Content

Support Center